AstraZeneca scores Chinese approval for heart failure therapy Forxiga
AstraZeneca said that Forxiga (dapagliflozin) has secured approval in China for its use in the reduction of the risk of cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults having heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). The approval for the sodium-glucose co-transporter 2 inhibitor (SGLT2 inhibitor) from the Chinese […]
AstraZeneca gets BRILINTA FDA approval for reducing risk of stroke in acute ischemic stroke or high-risk transient ischemic attack
November 8, 2020 No Comment
BRILINTA FDA approval : AstraZeneca has bagged approval for BRILINTA (ticagrelor) from the US Food and Drug Administration for its use in reducing the risk of stroke in patients having acute ischemic stroke or high-risk transient ischemic attack (TIA). The FDA approval was driven by the positive results from the THALES phase 3 clinical trial […]
Continue reading …
AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with chronic kidney disease (CKD), irrespective of type 2 diabetes (T2D). According to the US Centers for Disease Control and Prevention (CDC), chronic kidney disease is a serious, progressive condition defined […]
Continue reading …
Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The financial terms of the deal were not disclosed. AstraZeneca intends to take the PCSK9 inhibitor program into clinical trials in 2021 for dyslipidemia and also familial hypercholesterolemia. People having dyslipidemia, […]
Continue reading …COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response
July 20, 2020 No Comment
COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine (AZD1222) to be well tolerated besides generating strong responses in all evaluated participants against the COVID-19 causing SARS-CoV-2 virus. The early-stage COVID-19 vaccine trial is being led by Oxford University, […]
Continue reading …
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults after an acute myocardial infarction (MI) or heart attack. The fast track designation for the oral once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor is based on […]
Continue reading …
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]
Continue reading …
AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in patients aged 12 years and older, and with an eosinophilic phenotype. FASENRA is a monoclonal antibody which directly binds to the […]
Continue reading …
Business News Today
- Scanpoint Geomatics wins contract from BiharShariff Smart City
- Arbuthnot Banking sells Tay mortgage portfolio to OneSavings Bank
- Clothing retailer Gap to open $140m Customer Experience Center in Longview
- Kiwi insurer Tower to acquire legacy portfolio of ANZ
- World Insurance Associates acquires Corporate Risk Services in Arkansas
- Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
- Kotak Mahindra Bank acquires stake in new fintech company Ferbine
- Infosys to expand Pennsylvania Retirement Services Center of Excellence
- Energean takes full ownership of Israeli subsidiary
- Merck to acquire US biotech company Pandion Therapeutics for $1.8bn